- Home
- NVGS vs SAVA Comparison
NVGS vs SAVA Comparison
Compare NVGS & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVGS
- SAVA
- Stock Information
- Founded
- NVGS 1997
- SAVA 1998
- Country
- NVGS United Kingdom
- SAVA United States
- Employees
- NVGS N/A
- SAVA N/A
- Industry
- NVGS Marine Transportation
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- NVGS Consumer Discretionary
- SAVA Health Care
- Exchange
- NVGS Nasdaq
- SAVA Nasdaq
- Market Cap
- NVGS 1.1B
- SAVA 1.3B
- IPO Year
- NVGS N/A
- SAVA N/A
- Fundamental
- Price
- NVGS $15.94
- SAVA $32.18
- Analyst Decision
- NVGS Strong Buy
- SAVA Strong Buy
- Analyst Count
- NVGS 3
- SAVA 3
- Target Price
- NVGS $22.00
- SAVA $111.50
- AVG Volume (30 Days)
- NVGS 190.2K
- SAVA 1.6M
- Earning Date
- NVGS 11-06-2024
- SAVA 11-07-2024
- Dividend Yield
- NVGS 1.26%
- SAVA N/A
- EPS Growth
- NVGS 13.48
- SAVA N/A
- EPS
- NVGS 1.12
- SAVA N/A
- Revenue
- NVGS $564,280,000.00
- SAVA N/A
- Revenue This Year
- NVGS $3.05
- SAVA N/A
- Revenue Next Year
- NVGS $2.17
- SAVA N/A
- P/E Ratio
- NVGS $14.36
- SAVA N/A
- Revenue Growth
- NVGS 5.99
- SAVA N/A
- 52 Week Low
- NVGS $13.85
- SAVA $8.79
- 52 Week High
- NVGS $18.18
- SAVA $42.20
- Technical
- Relative Strength Index (RSI)
- NVGS 50.43
- SAVA 64.80
- Support Level
- NVGS $15.25
- SAVA $25.72
- Resistance Level
- NVGS $16.57
- SAVA $29.49
- Average True Range (ATR)
- NVGS 0.39
- SAVA 2.63
- MACD
- NVGS 0.06
- SAVA 0.48
- Stochastic Oscillator
- NVGS 52.27
- SAVA 82.89
About NVGS Navigator Holdings Ltd. (Marshall Islands)
Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture).
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.